Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 crossover study of sepiapterin versus sapropterin in phenylketonuria
NL-OMON60213Phase 3Completed
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Aug 2024
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sepiapterin and sapropterin in phenylketonuria (PKU) (2 arms), sponsored by PTC Therapeutics, Inc. Primary endpoint: Mean change in blood phenylalanine from baseline to Weeks 3 and 4 of each treatment period. Started Aug 2024; status: completed.
02
Drugs
sepiapterinsapropterin
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NL-OMON60213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60213.